Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus letrozole versus lapatinib plus capecitabine as first-line treatment for ER-positive/HER2-positive metastatic breast cancer
2010-021090-36Phase 2Terminated
- Sponsor
- AOU Policlinico di Modena
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Lapatinib + letrozole with Lapatinib + capecitabine (2 arms). Primary endpoints: Time to progression 1, Time to progression 2 and 5 more. Started Dec 2010; status: terminated.
02
Drugs
lapatinibletrozolecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-021090-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021090-36.